Dutasteride
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Dutasteride.png | |
| Dutasteride
| |
| Systematic (IUPAC) name | |
| (5α, 17β)-N-{2,5 bis(trifluoromethyl) phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | G04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C27H30F6N2O2 |
| Mol. mass | 528.53 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 60% |
| Protein binding | 99% |
| Metabolism | Hepatic (CYP3A4-mediated) |
| Half life | 5 weeks |
| Excretion | Fecal |
| Therapeutic considerations | |
| Pregnancy cat. |
X(US) Not to be handled by pregnant women |
| Legal status | |
| Routes | Oral |
|
WikiDoc Resources for Dutasteride | |
|
Articles | |
|---|---|
|
Most recent articles on Dutasteride Most cited articles on Dutasteride | |
|
Media | |
|
Powerpoint slides on Dutasteride | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Dutasteride at Clinical Trials.gov Clinical Trials on Dutasteride at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Dutasteride
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Dutasteride Discussion groups on Dutasteride Patient Handouts on Dutasteride Directions to Hospitals Treating Dutasteride Risk calculators and risk factors for Dutasteride
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Dutasteride | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Dutasteride (marketed as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost) is a 5-alpha-reductase inhibitor, a drug which inhibits the conversion of testosterone into dihydrotestosterone (DHT). It is used to treat conditions caused by DHT, such as benign prostatic hyperplasia (BPH).
Classification and Method of Action
Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). Finasteride also belongs to this group. Dutasteride inhibits both isoforms of 5-alpha reductase, while finasteride inhibits only one. But a clinical study done by GlaxoSmithKline, the EPICS trial, did not find dutasteride to be more effective than finasteride in treating BPH.
Uses
While dutasteride is officially approved to treat enlargement of the prostate gland. Clinical trials for dutasteride as a hair loss drug were undertaken, but called off in late 2002. The reason the trials were called off is not publicly known. Industry sources speculate that Avodart would have been seen as too similar to Propecia to have proved profitable as a hair loss treatment.
In December 2006, Avodart manufacturer GlaxoSmithKline embarked on a new Phase III, six month study in Korea to test the safety, tolerability and effectiveness of a once-daily dose of dutasteride (0.5mg) for the treatment of male pattern baldness in the vertex region of the scalp (types IIIv, IV and V on the Hamilton-Norwood scale).[1] The future impact that this study will have on the FDA's approval or disapproval of Avodart for the treatment of male pattern baldness in the United States is yet to be determined.
See also
External links
- Effectiveness of Dutasteride as a treatment for Male Pattern Baldness, as reported by Science Daily.
- Official site
- http://www.hairlosshelp.com/html/Dutasteride_hair_loss_trials.cfm
- Information on suspended trials for Avodart as a hair loss treatment Accessed 02/09/2006
References
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
